Vonoprazan-based therapy versus proton-pump inhibitor-based therapy for eradication of Helicobacter pylori: a randomized controlled trial
Abstract
Helicobacter pylori
infection is a common infection that produces multiple intestinal and extraintestinal diseases, and the overall eradication rate is less than desirable. The suboptimal acid suppression had an important role in reducing the eradication rate. Our study aimed to compare the potent acid suppressor (Vonoprazan)versus pantoprazole in the eradication of
H. pylori
.
A randomized clinical trial was conducted on 100 patients infected with
H. pylori
and divided into two equal groups: group 1 treated with levofloxacin-based triple therapy and proton-pump inhibitor, while group 2 treated with levofloxacin-based triple therapy and Vonoprazan.
The eradication rate was significantly higher in Vonoprazan-containing regimens (92%) than proton-pump inhibitor with a 76% eradication rate, while there were no significant side effects between the two groups.
Vonoprazan-based therapy is a safe, well-tolerated, promising and effective treatment option for
H. pylori
eradication, offering a higher success rate compared to pantoprazole-based regimens.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 100 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.